Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer

Pérez-Carbonell, Lucía; Ruiz-Ponte, Clara; Guarinos, Carla; Alenda, Cristina; Payá, Artemio; Brea, Alejandro; Egoavil, Cecilia M.; Castillejo, Adela; Barberá, Victor M.; Bessa, Xavier; Xicola, Rosa M.; Rodríguez-Soler, María; Sánchez-Fortún, Cristina; Acame, Nuria; Castellví-Bel, Sergi; Piñol, Virgínia; Balaguer, Francesc; Bujanda, Luis; De-Castro, María-Luisa; Llor, Xavier
June 2012
Gut;Jun2012, Vol. 61 Issue 6, p865
Academic Journal
Background The selection of patients for genetic testing to rule out Lynch syndrome is currently based on fulfilment of at least one of the revised Bethesda criteria followed by mismatch repair (MMR) status analysis. A study was undertaken to compare the present approach with universal MMR study-based strategies to detect Lynch syndrome in a large series of patients with colorectal cancer (CRC). Methods 2093 patients with CRC from the EPICOLON I and II cohorts were included. Immunohistochemistry for MMR proteins and/or microsatellite instability (MSI) analysis was performed in tumour tissue. Germline MLH1 and MSH2 mutation analysis was performed in patients whose tumours showed loss of MLH1 or MSH2 staining, respectively. MSH6 genetic testing was done in patients whose tumours showed lack of MSH6 expression or a combined lack of MSH2 and MSH6 expression but did not have MSH2 mutations. PMS2 genetic testing was performed in patients showing isolated loss of PMS2 expression. In patients with MSI tumours and normal or not available MMR protein expression, all four MMR genes were studied. Results A total of 180 patients (8.6%) showed loss of expression of some of the MMR proteins and/or MSI. Four hundred and eighty-six patients (23.2%) met some of the revised Bethesda criteria. Of the 14 (0.7%) patients who had a MMR gene mutation, 12 fulfilled at least one of the revised Bethesda criteria and two (14.3%) did not. Conclusions Routine molecular screening of patients with CRC for Lynch syndrome using immunohistochemistry or MSI has better sensitivity for detecting mutation carriers than the Bethesda guidelines. INSET: Significance of this study.


Related Articles

  • A Further Investigation of Combined Mismatch Repair and BRAFV600E Mutation Specific Immunohistochemistry as a Predictor of Overall Survival in Colorectal Carcinoma. Luey, Nathan; Toon, Christopher W.; Sioson, Loretta; Clarkson, Adele; Watson, Nicole; Cussigh, Carmen; Kedziora, Andrew; Pincott, Stuart; Pillinger, Stephen; Evans, Justin; Percy, John; Engel, Alexander; Schnitzler, Margaret; Gill, Anthony J. // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Mutation specific immunohistochemistry (IHC) is a promising new technique to detect the presence of the BRAFV600E mutation in colorectal carcinoma (CRC). When performed in conjunction with mismatch repair (MMR) IHC, BRAFV600E IHC can help to further triage genetic testing for Lynch Syndrome. In...

  • Microsatellite Instability and Colorectal Cancer. Geiersbach, Katherine B.; Samowitz, Wade S. // Archives of Pathology & Laboratory Medicine;Oct2011, Vol. 135 Issue 10, p1269 

    Context.--About 15% of colorectal cancers are characterized by genomic microsatellite instability, and of these, about 1 in 5 (2%-4% overall) are due to Lynch syndrome, a dominantly inherited condition predisposing the patient to cancers of multiple organ systems, including the gastrointestinal...

  • Identification of Individuals at Risk for Lynch Syndrome Using Targeted Evaluations and Genetic Testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer Joint Practice Guideline. Weissman, Scott; Burt, Randall; Church, James; Erdman, Steve; Hampel, Heather; Holter, Spring; Jasperson, Kory; Kalady, Matt; Haidle, Joy; Lynch, Henry; Palaniappan, Selvi; Wise, Paul; Senter, Leigha // Journal of Genetic Counseling;Aug2012, Vol. 21 Issue 4, p484 

    Identifying individuals who have Lynch syndrome (LS) involves a complex diagnostic work up that includes taking a detailed family history and a combination of various genetic and immunohistochemical tests. The National Society of Genetic Counselors (NSGC) and the Collaborative Group of the...

  • Hereditary Nonpolyposis Colorectal Cancer (HNPCC)/Lynch Syndrome. Steinke, Verena; Engel, Christoph; Büttner, Reinhard; Schackert, Hans Konrad; Schmiegel, Wolff H.; Propping, Peter // Deutsches Aerzteblatt International;1/18/2013, Vol. 110 Issue 3, p32 

    Background: Hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) is a genetic disease of autosomal dominant inheritance. It is caused by a mutation in one of four genes of the DNA mismatch repair system and confers a markedly increased risk for various types of cancer, particularly...

  • A case of squamous cell carcinoma of the skin due to the molecularly confirmed Lynch Syndrome. Sorscher, Steven // Hereditary Cancer in Clinical Practice;9/11/2015, Vol. 13 Issue 1, p1 

    Patients with Lynch Syndrome are at high risk for developing a variety of cancers including cancers of the colon or rectum, small bowel, stomach, uterus, renal pelvis, ureter, biliary tract, ovaries, brain and pancreas (N Engl J Med 348: 919-32, 2003; Gut 57:1097-101, 2008; NCCN, Inc Guideline....

  • The Mutational Spectrum of Lynch Syndrome in Cyprus. Loizidou, Maria A.; Neophytou, Ioanna; Papamichael, Demetris; Kountourakis, Panteleimon; Vassiliou, Vassilios; Marcou, Yiola; Kakouri, Eleni; Ioannidis, Georgios; Philippou, Chrystalla; Spanou, Elena; Tanteles, George A.; Anastasiadou, Violetta; Hadjisavvas, Andreas; Kyriacou, Kyriacos // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Lynch syndrome is the most common form of hereditary colorectal cancer and is caused by germline mutations in the mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2. Mutation carriers have an increased lifetime risk of developing colorectal cancer as well as other extracolonic tumours. The...

  • Lynch Syndrome: An Updated Review. Sehgal, Rishabh; Sheahan, Kieran; O'Connell, Patrick R.; Hanly, Ann M.; Martin, Sean T.; Winter, Desmond C. // Genes;Sep2014, Vol. 5 Issue 3, p497 

    Lynch syndrome is one of the most common cancer susceptibility syndromes. Individuals with Lynch syndrome have a 50%-70% lifetime risk of colorectal cancer, 40%-60% risk of endometrial cancer, and increased risks of several other malignancies. It is caused by germline mutations in the DNA...

  • Immunohistochemistry and microsatellite instability analysis in molecular subtyping of colorectal carcinoma based on mismatch repair competency. Lin Yuan; Yayun Chi; Weixiang Chen; Xiaochen Chen; Ping Wei; Weiqi Sheng; Xiaoyan Zhou; Daren Shi // International Journal of Clinical & Experimental Medicine;2015, Vol. 8 Issue 11, p20988 

    Mismatch repair defective (MMRd) colorectal carcinoma (CRC) is a distinct molecular phenotype of colorectal cancer, including 12% of sporadic CRC and 3% of Lynch Syndrome. In order to investigate the clinicopathological characteristics of MMRd colorectal carcinoma, and to find the most effective...

  • Universal Versus Targeted Screening for Lynch Syndrome: Comparing Ascertainment and Costs Based on Clinical Experience. Erten, Mujde; Fernandez, Luca; Ng, Hank; McKinnon, Wendy; Heald, Brandie; Koliba, Christopher; Greenblatt, Marc; Erten, Mujde Z; Fernandez, Luca P; Ng, Hank K; McKinnon, Wendy C; Koliba, Christopher J; Greenblatt, Marc S // Digestive Diseases & Sciences;Oct2016, Vol. 61 Issue 10, p2887 

    Background: Strategies to screen colorectal cancers (CRCs) for Lynch syndrome are evolving rapidly; the optimal strategy remains uncertain.Aim: We compared targeted versus universal screening of CRCs for Lynch syndrome.Methods: In 2010-2011, we employed...


Read the Article


Sign out of this library

Other Topics